the www.neurologix.net web site and intergrate the headlines on their home page. The latest news points to an interview by Wall Street dot net of Neurologix CEO John Mordock as he explains the exciting completion (and success) of Phase 2 Gene Therapy trials on 12 Parkinson's patients. And goes on to explain the start of Phase 3 trials beginning in the first quater of 07 which is expected to conclude in 18 months.

This is powerful stuff. A probable cure within two years via the technology of Gene Therapy, for 1.5 million Americans suffering the ills of Parkinson's, and a further 1 million in developed nations around the world.

Neurologix will have no competition once their G.T. trials are concluded. Any other human trials using stem cells (for instance) are seemingly years away.The Neurologix shares are a give away at .85 cents. A good time to triple double your money perhaps, by investing in a few Neurologix shares now. If this thing takes off, and indications appear more than favourable, Neurologix shares are going to make a lot of individuals plenty of spondulous (money) and satisfy 2 million plus individuals currently living the debilitating Parkinson's experience.

GO HARD SCIENCE



What is exciting about Neurologic's Gene Therapy research is the fact success in human trials are well advanced and commercialization for a cure for PARKINSON'S is but a nano second away.